Natural history of ALS: Symptoms, strength, pulmonary function, and disability

Neurology

Volumn 47, Issue 4 SUPPL., 1996, Pages

  Brooks, Benjamin Rix ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RILUZOLE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; DISABILITY; ELECTROMYOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MUSCLE ATROPHY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY FAILURE; TREATMENT OUTCOME;

EID: 0029845015     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.4_suppl_2.71s     Document Type: Article

References (21)

1. Brooks BR. Clinical epidemiology of arayotrophic lateral sclerosis. Neurol Clin 1996;14:399-420.
2. Brooks BR, Shodis KA, Lewis DH, et al. Natural history of amyotrophic lateral sclerosis: quantification of symptoms, signs, strength and function. In: Serratrice GT, Munsat TL, eds. Pathogenesis and therapy of amyotrophic lateral sclerosis. Advances in neurology, vol 68. Philadelphia: Lippincott-Raven, 1995:163-184.
3. Sobue G, Sahashi K, Takahashi A, et al. Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. Neurology 1983; 33:654-657.
4. Brooks BR. A summary of the current position of TRH in ALS therapy. Ann NY Acad Sci 1989;553:431-461.
5. Brooks BR, Sufit RL, Clough JA, et al. Isokinetic and functional evaluation of muscle strength over time in amyotrophic lateral sclerosis. In: Munsat TL, ed. Quantitation of neurologic defect. Boston: Butterworths, 1989:143-154.
6. Brooks BR, DePaul R, Tan Y-D, Sanjak M, Sufit RL, Robbins R. Motor neuron disease. In: Schoenberg BS, Porter R, eds. Controlled clinical trials in neurology. Norwood: Marcel Dekker, 1990:249-281.
7. Brooks BR, Sufit RL, DePaul R, Tan Y-D, Sanjak M, Robbins J. Design of clinical therapeutic trials in amyotrophic lateral sclerosis. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. Advances in neurology, vol 56. New York: Raven Press, 1991:521-546.
8. Li T-M, Alberman E, Swash M. Clinical features and associations of 560 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53:1043-1045.
9. Li T-M, Swash M, Alberman E, Day SJ. Diagnosis of motor neuron disease by neurologists: a study in three countries. J Neurol Neurosurg Psychiatry 1991;54:980-983.
10. Brooks BR, Lewis D, Rawling J, et al. The natural history of amyotrophic lateral sclerosis. In: Williams AC, ed. Motor neuron disease. London: Chapman & Hall, 1994;131-169.
11. Andres PL, Skerry LM, Munsat TL. Measurement of strength in neuromuscular diseases. In: Munsat TL, ed. Quantitation of neurologic deficit. Boston: Butterworths, 1989:87-100.
12. Munsat TL, Andres PL, Skerry LM. The use of quantitative techniques to define amyotrophic lateral sclerosis. In: Munsat TL, ed. Quantitation of neurologic deficit. Boston: Butterworths, 1989:129-142.
13. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409-413.
14. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43: 1316-1322.
15. Leone M, Chandra V, Schoenberg BS. Motor neuron disease in the United States, 1971 and 1973-1978: patterns of mortality and associated conditions at the time of death. Neurology 1987;37:1339-1343.
16. James CM, Harper PS, Wiles CM. Motor neurone disease: a study of prevalence and disability. Q J Med 1994;87: 693-699.
17. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical Limits of Amyotrophic Lateral Sclerosis" Workshop contributors. J Neurol Sci 1994;124(suppl):96-107.
18. Munsat TL. Airlie House Guidelines: therapeutic trials in amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases of the World Federation of Neurology Research Group on Neuromuscular Diseases and the Airlie House "Therapeutic Trials in ALS" Workshop contributors. J Neurol Sci 1995;129(suppl):1-10.
19. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.
20. ALS CNTF Treatment Study Phase I-II Study Group. The ALS Functional Rating Scale: Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996;53:141-147.
21. Brooks BR. Emerging therapeutics in amyotrophic lateral sclerosis: palliative therapies at the advent of the 21st century. Clin Neurosci (in press).